ScreenerHero
PCRXPacira Biosciences, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · pacira.com
24.02USD-1.38%Mkt Cap: 958.52M $P/E: 69.60

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The co…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap958.52M $
Enterprise Value1.11B $
Revenue (TTM)746.16M $
Gross Profit576.66M $
Net Income (TTM)7.03M $
Revenue/Share17.93 USD
Last Price24.02 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees825
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS6951271005
Valuation
P/E (Trailing)69.60
P/E (Forward)6.91
PEG11.21
EV/EBITDA8.96
EV/Revenue1.49
P/S1.27
P/B1.41
EPS (TTM)0.34
EPS (Forward)3.45
52W Range
18.8059% of range27.66
52W High27.66 USD
52W Low18.80 USD
Profitability
Gross Margin79.39%
Oper. Margin6.17%
EBITDA Margin16.61%
Profit Margin0.97%
ROE1.01%
ROA0.56%
Growth
Revenue Growth6.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF151.99M $
CapEx (TTM)15.33M $
FCF Margin13.18%
FCF Yield10.26%
Net Debt161.09M $
Net Debt/EBITDA1.30
Balance Sheet
Debt/Equity0.60
Current Ratio5.04
Quick Ratio3.21
Book Value/Sh16.87 USD
Cash/Share6.298 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.00 USD
Upside (mean)+24.9%
Target Range23.00 USD – 38.00 USD
$23.00+24.9% to mean$38.00
# Analysts7
Ownership
Shares Out.39.35M
Float36.20M
Insiders1.74%
Institutions113.51%
Short Interest
Short Ratio14.2d
Short % Float26.04%
Short % Out.18.11%
Shares Short7.21M
Short (prev mo.)6.59M
Technical
SMA 5024.83 (-3.3%)
SMA 20023.66 (+1.5%)
Beta0.27
S&P 52W Chg18.16%
Avg Vol (30d)603.79K
Avg Vol (10d)618.17K
Technical Indicators
RSI (14)46.5
MACD-0.4451
MACD Signal-0.1337
MACD Hist.-0.3115
BB Upper28.13 USD
BB Middle25.34 USD
BB Lower22.54 USD
BB Width22.06%
ATR (14)1.022 USD
Vol Ratio (20d)0.47x